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^  Protein kinase C (PKC) is an enzyme involved in the regulation of cellular growth, proliferation, and differentia­
tion in a number of tissues including the anterior pituitary, in which it is also believed to play a role in hormone secre­
tion. Protein kinase C activity and expression have been found to be greater in adenomatous pituitary cells than in nor­
mal human and rat pituitary cells and higher in invasive pituitary tumor cells than in noninvasive ones. Inhibition of 
PKC activity has been shown in a variety of tumor cells to inhibit growth in a dose-related fashion. The purpose of the 
current study was to determine whether hypericin, a potent inhibitor of PKC activity that may be administered clini­
cally, alters the growth and proliferation in established pituitary adenoma lines and to determine if inhibition of PKC 
activity induces apoptosis, as reported in some other tumor cell types. Two established pituitary adenoma cell lines, 
AtT-20 and C il I,( '. were treated with hypericin in tissue culture for defined periods following passage. Inhibition of 
growth was found to be dose dependent in all three cell lines in low micromolar concentrations of hypericin, as deter­
mined by viable cell counts, methylthiotetrazole assay, and pH]thymidine uptake studies. Concentrations of hypericin 
as low as 100 nM also induced apoptosis in these established lines, whereas treatment of normal human fibroblasts 
with a concentration of 10 p,M failed to induce apoptosis. The potential use of hypericin in the therapy of pituitary ade­
nomas warrants additional in vitro investigations with the aim of later moving toward therapeutic trials in selected 
patients in whom surgical or medical therapy has failed.
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A ctivation  of specific cell surface receptors results 
in the hydrolysis of phosphoinositides and the
1. V  generation of diglycerides and inositol phosphates. 
One of these diglycerides, diacylglycerol, activates pro­
tein kinase C (PKC), a family of closely related iso­
enzymes involved in signal transduction within the cell. 
Protein kinase C is involved in the regulation of a number 
of cellular events, including growth and differentiation in 
a wide range of tissues. Protein kinase C activity has been 
examined in a variety of tumor cells, including colon 
and breast carcinomas, malignant gliomas, and pituitary 
adenomas. In pituitary adenoma cell lines, levels of PKC 
activity and expression were found to be greater than 
those found in normal human and rat pituitary cells; in 
invasive adenoma cells, levels were even greater than 
those in noninvasive adenoma cells, suggesting that PKC 
activity may have a functional role in the rate of growth 
and the invasive properties of these tumor cells .4,12’24’36 In 
this regard, a point mutation has been recently reported in 
the a-PK C  complementary DNA sequences of four inva­
sive adenomas that was absent in the noninvasive adeno­
mas analyzed .3
Hypericin, a conjugated quinone biosynthesized by 
members of the plant genus Hypericum, is a photodynam­
ic pigment that has been found in vitro  to oxidize lipids, 
amino acids, and proteins and to disrupt the normal func­
tion of cellular mem branes .14’17’18’31’34 Hypericin exhibits 
antidepressant, antiviral, and (it has been suggested) anti­
neoplastic properties in some cell types .5,6’10’20-22’31’33 H y­
pericin has recently been shown to be a potent inhibitor 
of PKC as well as of other cellular enzym es .16,31’32 This 
chemical has also been demonstrated to be a potent in­
hibitor of glioma growth and an inducer of apoptosis in 
these cells .6,10’11 These effects have been positively corre­
lated with PKC activity, suggesting that inhibition of PKC 
is involved in these processes.
Cell growth and apoptosis are regulated by a limited set 
of signal transduction systems that regulate second mes­
sengers involved in the phosphorylation of proteins, ulti­
mately controlling cellular metabolism and gene expres­
sion. Apoptosis occurs in a multitude of both normal and 
pathological processes. Apoptosis differs from necrosis 
morphologically by the presence of blebbing of plasma 
and nuclear membranes, by chromatin condensation and
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fragmentation, and biochemically by the activation of 
endonucleases and proteases that result in characteristic 
fragmentation o f nuclear DNA. Selective manipulation of 
this process of apoptosis may provide a mechanism by 
which a number of pathological conditions, including dys- 
regulated cell growth, may be altered.
The present study was undertaken to determine if  hy­
pericin, a drug used as a clinical antidepressant and cur­
rently undergoing evaluation for use as an antiretroviral 
agent in treating patients with the human immunodefi­
ciency virus, could inhibit growth and induce apoptosis 
in established pituitary adenoma cell lines in vitro. Here 
we show that the agent is a potent inhibitor o f both PKC 
activity and adenoma growth and induces apoptosis in 
these cells.
Materials and Methods
Pituitary Adenoma Cell Cultures
We used the previously characterized rat pituitary adenoma cell 
lines AtT-20 and GH.C, (American Type Culture Collection, Rock­
ville, MD) in this study. The AtT-20 pituitary adenoma culture was 
maintained in 25-cm3 tissue culture flasks in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine serum, peni­
cillin/streptomycin (100 U/ml:10 ^g/ml), and 10 mmol/L Hepes 
buffered to a pH of 7.0. The GH.C, cultures were grown under iden­
tical conditions, except that the medium was supplemented with 5% 
fetal bovine serum. Cells were grown at 37°C in a modified 5% CO, 
incubator.
Protein Kinase C Assay
Flasks (25 cm3) containing the two established cell lines (in the 
presence or absence of hypericin) were rinsed with ice-cold phos­
phate-buffered saline, then rinsed with a homogenizing buffer 
containing 50 mM Tris-HCl, 2 mM dithiothreitol, 1 mM phenyl- 
methylsulfonylfluoride, and 2 mM ethyleneglycol-Mv-(beta-amino- 
ethylether) N,N,iV',iV'-tetraacetic acid. The cells were subsequently 
scraped from the culture flasks, suspended in 2 ml of the solution, 
and homogenized with the homogenate centrifuged at 100,000 G 
for 60 minutes, and designated as the cytosolic fraction. The pellet 
was resuspended in 2 ml of the buffer containing 1 % Triton X-l 00, 
homogenized, gently mixed for 30 minutes, centrifuged at 100,000 
G for 60 minutes, and designated as the particulate fraction. These 
procedures were performed at 4°C, with the designated enzyme 
fractions then stored at —70°C prior to the PKC assay.
The method used to assay for PKC activity (adenosine triphos­
phate (ATP) transfer into lysine-rich histone) has been previously 
published.9 For each cell culture condition, three separate cultures 
were assayed. Mean and standard error values from the separate 
experiments were then calculated and are presented below.
Cellular Viability and Proliferation Assays
Tumor cell viability and proliferation were tested using the as­
says specified below. Regardless of the assay performed, all control 
and treatment cultures were maintained under similar cell density 
and culture conditions in the dark following addition of hypericin.
Methylthiotetrazole Assay. A modified colorimetric assay based 
on the selective ability of living cells to reduce the yellow salt 
MTT (3-[4,5-dimethylthiozol-2-yll-2,5 diphenyl tetrazolium bro­
mide or methylthiotetrazole) to formazan was used to quantitate 
hypericin-mediated cytotoxicity. After the cells were cultured in 
the presence of hypericin (LC Service Corp., Woburn, MA) for 
various lengths of time, 5 mg/ml MTT (Sigma Chemical Co., St. 
Louis, MO) was added to each well for a period of 4 hours. 
Following formation of the formazan crystals, the culture medium 
supernatant was removed from the wells without disruption of the 
formazan precipitate. The formazan crystals were then dissolved 
in 150 ^1/well dimethyl sulphoxide (100%). The absorbance was
Fig. I. Graph displaying hypericin inhibition of protein kinase 
C (PKC) activity in the established pituitaiy adenoma cell line 
AtT-20. A marked inhibition of total PKC activity occurs in AtT- 
20 cells following incubation with 10 hypericin. The PKC 
activity units are expressed as nanomoles of adenosine triphos­
phate "transferred per minute per milligram of protein.9 Measure­
ments of total PKC activity obtained as early as 2 hours after treat­
ment indicate significantly decreased PKC activity in the treated 
cultures. All values represent the mean of triplicate treated cul­
tures plus the standard error of the mean. Asterisks indicate values 
significantly different from controls (one-way ANOVA, Duncan’s 
multiple comparison; *p <  0.05).
measured at 570 nm using a microplate spectrophotometer 
(MR700; Dynatech, Chantilly, VA) interfaced with a Macintosh 
computer. It has previously been shown that viable cell numbers 
correlate with optical density as determined by the MTT as­
say I3.2S.37.3S
Trypan Blue Dye Exclusion Assay. Following treatment of the 
cell cultures in varying concentrations of hypericin (0-20 ^M), 
the culture plates were centrifuged, their medium was decanted, 
the cells were washed with PBS, and trypan blue dye was added to 
the cell suspension. Three hundred cells from each of three cul­
tures per treatment group were counted on coded specimens by 
observers blinded to the groups. The percent viability (dye exclu­
sion) was then calculated and recorded.
[3H]Thymidine Uptake Assay. To offer data complementary to 
those yielded by the MTT viability and trypan blue exclusion 
assays described above, pHlthymidine uptake was determined as 
a measure of cellular proliferation. Our method for determining 
rates of cell proliferation using pHlthymidine uptake has been pre­
viously published.s<) In these studies, hypericin was added to wells 
containing cells in midlogarithmic growth at predetermined con­
centrations in replicates of four. Radioactive thymidine uptake was 
then determined following a 72-hour incubation in concentrations 
of hypericin ranging from 0 to 20 ^M. These concentrations pre­
viously have been demonstrated to lie within the range known to 
modulate PKC in vitro.6-*32 It has already been shown that uptake 
of pHlthymidine into cells using this technique is a reliable index 
of DNA synthesis.7
Apoptosis Assay
After passage, each cell line was seeded at a density of 2.5 X 105 
cells per 5 ml of medium in 25-cm3 tissue culture flasks and subse­
quently treated with hypericin for 72 hours. Washed cell pellets 
were resuspended in lysis buffer (0.5% sodium dodecyl sulfate, 0.1 
mol/L NaCl, 10 mmol/L N,Af'-l,2-ethanedyl-tes-(iV-(carboxy- 
methyDglycine), 0.01 mol/L Tris-HCl, pH 8.0) in the presence of
0.1 mg/m’l proteinase K for 12 to 18 hours at 37°C. The samples 
were twice extracted with phenol/chloroform/isoamyl alcohol and 
precipitated by addition of a 0.10 vol of 2 mol/L sodium acetate and 
2.5 vol of ethanol. These were then resuspended in 10 mmol/L 
N,iV'-l ,2-ethanedyl-tes-(iV-(carboxymethyl)glycine), at a pH of 7.4,
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Fig. 2. Graphs showing hypericin inhibition of pituitary adenoma cell growth. Results of a methy lthiotetrazole (MTT) 
assay indicate a dose-related decrease in the absorbance of AtT-20 cells (correlating with viable cell numbers) following 
administration of hypericin for a period of 3 (upper left) or 6 (upper center) days. The inhibition of growth was facilitat­
ed slightly by the longer incubation period. Similarly, the absorbance of GH,C, cells decreased in a dose-related manner 
in the presence of hypericin for 4 days (upper right). All values represent the mean of quintuplicate wells + the standard 
error of the mean (SEM). Similar to the results of the MTT assay, cell viability, as determined by the trypan blue dye 
exclusion test, was decreased in cell cultures treated with increasing concentrations of hypericin in both AtT-20 (low ’er
+
cell viability assays, pHJthymidine uptake was determined in AtT-20 cells following incubation with hypericin for 72 
hours (lower right). Thymidine uptake was inhibited significantly at doses of 1 ^M hypericin and greater for this time
+
are significantly different from controls (one-way ANOVA, Duncan’s multiple comparison; *p< 0.05, **p <  0.01).
then treated with DNase-free RNase for 2 to 4 hours at 37°C. Equal 
amounts of DNA were electrophoresed on a 1.2% agarose gel con­
taining 0.5 mg/ml ethidium bromide, visualized by means of ultra­
violet fluorescence, and photographed. A low-passage human fi­
broblast line was treated concurrently under identical conditions as 
a nontransformed cell control.
Results
Hypericin Inhibition o f  Protein Kinase C Activity in the 
Pituitary Cell Line A tT-20
Protein kinase C activity was measured following treat­
ment with hypericin (Fig. 1). Total AtT-20 PKC activity 
levels after isolation o f cytosolic and particulate (mem­
brane) fractions were found to be consistent with pub­
lished levels in other pituitary tumor cells.412 After treat­
ment of AtT-20 cultures with 10 |xM hypericin, total PKC 
activity was inhibited significantly as early as 2 hours fol­
lowing treatment. Protein kinase C activity continued to 
decrease to approximately 25% of control activity after 24 
hours of treatment.
Hypericin Inhibition o f  Pituitary Adenom a Growth
An M TT assay was performed after treatment o f the
pituitary established cell lines with hypericin for various 
periods o f time over a range of concentrations to deter­
mine the effect o f this drug on cellular growth. Hypericin 
inhibited the growth o f the two established pituitary cell 
lines in a dose-related m anner in upper nanomolar and low 
micromolar concentrations (Fig. 2 upper left and right). In 
the established line AtT-20, the inhibitory effect increased 
with the duration of incubation from 3 to 6 days (Fig. 2 
upper left and center). Similar results were noted in line 
G H ^ , (Fig. 2 upper right).
To confirm the results o f the M TT assay, cell viability 
was determined following treatment with hypericin by 
trypan blue dye exclusion. As shown (Fig. 2 low er left and 
center) the viability of cells after treatment with hypericin 
at concentrations greater than I |xM decreased signifi­
cantly as early as 24 hours in culture. Cell death increased 
with treatment time and reached a maximum level at 72 
hours after treatment in both cell lines tested.
To explore the growth inhibition produced by hypericin 
further, [3H]thymidine uptake was determined in AtT-20 
cells following treatment with various concentrations of 
the drug (Fig. 2 low er right). Thymidine uptake decreased 
in a dose-related m anner after a 72-hour treatment with 
hypericin; significant inhibition was noted with concen­
trations as low as I |xM during this treatment period.
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Fig. 3. Ultraviolet fluorcsccncc photographs obtained after 
agarose gel clcctrophorcsis showing that hypcricin induccs apo­
ptosis in established pituitary adenoma ccll lines. Treatment of 
pituitary adenoma cclls with hypcricin and DNA isolation arc de­
scribed in Materials and Methods. The DNA that was isolated 
from the established adenoma ccll lines AtT-20 and GH.C, in the 
abscncc of hypcricin (Lane 0 ) and in the prcscncc of varying 
concentrations of hypcricin (values given in micromolar concen­
trations) were clcctrophorcscd in 1.2% agarose and stained with 
cthidium bromide (upper and center gels). Note the prcscncc of 
oligonuclcosomc-sized fragments, which producc a classic ladder 
pattern in the lanes containing DNA from treated cclls at doses of
0.1 and higher (arrowheads). The human fibroblast control 
ccll culture demonstrated no cvidcncc of DNA fragmentation after 
treatment with 10 hypericin on either gel (Lane FIB). The sizes 
of oligonuclcosomal fragments were determined by comparison to 
DNA size markers in Lane M. The DNA isolated from line AtT-20 
at various time periods after addition of 10 hypericin indicates 
the prcscncc of apoptosis after 24 and 72 hours of treatment dower 
gel). No evident DNA fragmentation was seen at the 6-hour time 
period.
Hypericin Induction o f  Apoptosis in Established Pituitary 
Adenoma Cell Lines
Following treatment of the cultures with hypericin for 
72 hours, adherent and floating cells were collected and 
subjected to subsequent purification and analysis of DNA 
by agarose gel electrophoresis. In both established pitu­
itary adenoma cell lines, AtT-20 and GH4C,, the clas­
sic ladder pattern of oligonucleosome-sized fragmented 
DNA, indicative of apoptosis, was noted following incu­
bation with hypericin in nanomolar concentrations (Fig. 
3 upper  and cen ter  gels). In contrast, no detectable DNA 
degradation was found in the untreated cells, as evidenced 
by the absence of an ethidium brom ide-stained substance 
in the region of the agarose gel corresponding to low-mo- 
lecular-weight DNA and the presence of a band of high- 
molecular-weight DNA. In the low-passage human fi­
broblast culture, no evidence of DNA fragmentation was 
detected when treated with hypericin at a concentration of 
10 |xM.
To determine the time course of DNA fragmentation, 
AtT-20 cells were treated for various time periods with
10 |xM hypericin. As shown in the lower gel in Fig. 3, 
oligonucleosomal DNA fragmentation was noted as early 
as 24 hours after treatment. No significant fragmentation 
was noted following the 6 -hour treatment period.
Discussion
The PKC signal transduction system has been shown to 
be involved in the regulation of cellular growth, differen­
tiation, and gene transcription .29 In pituitary cells, this 
enzyme is also believed to modulate hormone synthesis 
and secretion . l '2 l9 '23'“V 27'3a35 The PKC family currently 
consists of a minimum of 1 2  structurally distinct isoforms 
that have been separated into three categories based on 
cofactor requirem ents.15The classic PKCs, a , p,, P2and 7 , 
require calcium for activity and they are activated by the 
phorbol ester phorbol-12-m yristate-13-acetate (PMA), 
whereas the novel PKCs, 8 , e, and 0, possess activity in 
the absence of calcium and remain activated by PMA, and 
the atypical PKCs, £ and X, possess activity in the absence 
o f calcium and are not activated by PMA. Both calcium- 
dependent and -independent PKC isoenzymes have been 
found in normal and adenomatous pituitary cells, suggest­
ing their prominent role in signal transduction in anterior 
pituitary cells. At least five isozymes are expressed in 
pituitary cells ( a  p, 8  e, and £) with PK C ^ being ex­
pressed in rat GH4C, cells . 1— 5~27 The activation by PMA 
indicates that the classic and novel PKC isozymes present 
( a  P, 8 , e, and ^ )  may be involved in the regulation of 
growth and differentiation in pituitary adenomas. M ore­
over, prolactin secretion in GH4C, cells has recently been
e
Protein Kinase C in Growth Regulation and Induction o f  
Apoptosis
Inhibition of the high level of PKC activity in the pitu­
itary cell line AtT-20 by hypericin is identified in the cur­
rent study, with the drug exhibiting potent inhibition of 
enzyme activity in these cells. Furthermore, significant 
PKC inhibition was noted as early as 2 hours following
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treatment; this preceded the induction of apoptosis and the 
decrease in thymidine uptake and cell viability noted in 
these cell lines. Similarly, hypericin has been shown to 
inhibit malignant glioma growth and to be a potent induc­
er of apoptosis in these cells. 10,11 The correlation of PKC 
activity with cell growth and apoptosis suggests that the 
PKC enzyme system may be involved in the control of 
these processes and that inhibition of PKC may provide a 
potential avenue for clinical tumor growth inhibition in 
these cell types.
Hypericin as a Potential Antitumor Agent
As supported by data provided in the present study, 
hypericin is a potent inhibitor of PKC, as well as the 
epidermal growth factor receptor tyrosine kinase.16,32 Dif­
fering from more classic PKC inhibitors, such as stau­
rosporine, Ro31-8220, and tamoxifen, which competitive­
ly block the ATP catalytic site, hypericin inhibits PKC by 
interacting with the regulatory domain of this enzyme and 
displays more selectivity in its inhibitory actions than 
either staurosporine or tamoxifen. Hypericin has also been 
found in vitro to oxidize lipids, amino acids, and proteins 
and to disrupt the normal function of cellular membranes.
The mechanism of action of hypericin in its antineo­
plastic effect may be multifactorial and has recently been 
reviewed elsewhere.6 The drug's irreversible inhibition of 
the PKC enzyme, disruption of cellular membranes,18,31,34 
or formation of photoactive intermediates14,17,22 may ulti­
mately be involved in inhibition of cellular growth and 
induction of apoptosis in tumors with high PKC activity—  
in this case pituitary adenoma cells. The nontransformed 
human fibroblasts in the present study displayed no evi­
dence of cytotoxicity or DNA degradation after treatment 
with hypericin at doses that induced apoptosis in pituitary 
adenoma cells. The antiglioma activity of hypericin is cur­
rently being evaluated; 10 the observed effects of hypericin 
in the present study indicate that hypericin or related com­
pounds may also offer therapeutic potential in selected 
patients with pituitary adenomas in whom surgical and 
medical therapies have failed.
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